IL153398A0 - Stable gabapentin containing more than 20 ppm of chlorine ion - Google Patents

Stable gabapentin containing more than 20 ppm of chlorine ion

Info

Publication number
IL153398A0
IL153398A0 IL15339801A IL15339801A IL153398A0 IL 153398 A0 IL153398 A0 IL 153398A0 IL 15339801 A IL15339801 A IL 15339801A IL 15339801 A IL15339801 A IL 15339801A IL 153398 A0 IL153398 A0 IL 153398A0
Authority
IL
Israel
Prior art keywords
ppm
chlorine ion
stable gabapentin
stable
gabapentin containing
Prior art date
Application number
IL15339801A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22788993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL153398(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL153398A0 publication Critical patent/IL153398A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15339801A 2000-06-16 2001-06-15 Stable gabapentin containing more than 20 ppm of chlorine ion IL153398A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21196700P 2000-06-16 2000-06-16
PCT/US2001/019100 WO2001097612A1 (fr) 2000-06-16 2001-06-15 Gabapentine stable contenant plus de 20 ppm d'ions chlore

Publications (1)

Publication Number Publication Date
IL153398A0 true IL153398A0 (en) 2003-07-06

Family

ID=22788993

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15339801A IL153398A0 (en) 2000-06-16 2001-06-15 Stable gabapentin containing more than 20 ppm of chlorine ion

Country Status (12)

Country Link
US (1) US6531509B2 (fr)
EP (1) EP1289364B1 (fr)
AT (1) ATE255891T1 (fr)
AU (1) AU2001268426A1 (fr)
CA (1) CA2410867C (fr)
DE (2) DE1289364T1 (fr)
DK (1) DK1289364T3 (fr)
ES (1) ES2193008T3 (fr)
IL (1) IL153398A0 (fr)
PT (1) PT1289364E (fr)
TR (1) TR200302296T4 (fr)
WO (1) WO2001097612A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU95302A (sh) * 2000-06-16 2006-05-25 Teva Pharmaceutical Industries Ltd. Stabilni gabapentin koji ima ph u kontrolisanom rasponu
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
WO2004058168A2 (fr) * 2002-12-20 2004-07-15 Dynogen Pharmaceuticals, Inc. Methodes de traitement de troubles de la vessie non douloureux au moyen de modulateurs du canal calcique de la sous unite ?2?
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
WO2005046566A2 (fr) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Composition pharmaceutique stable
KR20060108692A (ko) * 2003-10-31 2006-10-18 알자 코포레이션 메트포르민의 개선된 흡수를 위한 조성물 및 제형
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CN101462975B (zh) * 2008-08-19 2012-07-25 宁波九胜创新医药科技有限公司 一种高纯度加巴喷丁的制备方法
CN116693410B (zh) * 2023-06-08 2024-06-07 浙江竹子制药有限公司 一种粒径可控的加巴喷丁制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2611690A1 (de) 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
US4894476A (en) 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US4960931A (en) 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
PH27359A (en) 1989-08-25 1993-06-21 Warner Lambert Co Process for cyclic amino acid anticonvulsant compounds
US5132451A (en) 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
DE3928184A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
DE3928182A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
US5319135A (en) 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
HU228772B1 (en) * 1998-05-15 2013-05-28 Warner Lambert Co Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
IL139298A0 (en) * 1998-05-15 2001-11-25 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same

Also Published As

Publication number Publication date
US20020061931A1 (en) 2002-05-23
PT1289364E (pt) 2004-04-30
WO2001097612A1 (fr) 2001-12-27
CA2410867A1 (fr) 2001-12-27
ES2193008T3 (es) 2004-07-01
DE60101476D1 (de) 2004-01-22
ATE255891T1 (de) 2003-12-15
EP1289364B1 (fr) 2003-12-10
EP1289364A4 (fr) 2003-08-06
DE1289364T1 (de) 2003-09-18
ES2193008T1 (es) 2003-11-01
US6531509B2 (en) 2003-03-11
AU2001268426A1 (en) 2002-01-02
CA2410867C (fr) 2003-12-09
DK1289364T3 (da) 2004-04-13
EP1289364A1 (fr) 2003-03-12
TR200302296T4 (tr) 2004-02-23
DE60101476T2 (de) 2004-05-27

Similar Documents

Publication Publication Date Title
IL153398A0 (en) Stable gabapentin containing more than 20 ppm of chlorine ion
YU31399A (sh) Inhibitori sintaze azot-monoksida
IL161187A0 (en) Liposome compositions containing metal ions and therapeutic agents
MXPA01012336A (es) Gel de silicon que contiene acido salicilico.
MX355976B (es) Composiciones antitranspirantes de eficacia mejorada que contienen estroncio.
MXPA04004109A (es) Composiciones cosmeticas anhidras que contienen compuestos de amonio cuaternario.
TW200510375A (en) New compounds
AU2015902A (en) Aluminum-zirconium antiperspirant salts with high peak 5 al content
WO1998023249A3 (fr) Compositions orales contenant des fluorures, pyrophosphates, peroxydes et des tensio-actifs non ioniques et/ou amphoteriques
MXPA04006542A (es) Composiciones bucales estables que contienen complejos de fosfopeptido de caseina y fluooruro.
TNSN05275A1 (en) Lactate containing pharmaceutical composition and uses thereof
DE69905170D1 (en) Thiazolopyrimidinderivate
MXPA03009572A (es) Formas de polialilamina con bajo contenido en sal.
ZA200104726B (en) Nano-emulsion of 5-aminolevulinic acid.
TNSN04206A1 (en) Novel perindopril salt and pharmaceutical compositions containing same
AU2249297A (en) Low ph germicidal iodine compositions having enhanced stability
HRP20030002A2 (en) STABLE GABAPENTIN HAVING pH WITHIN A CONTROLLED RANGE
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi
AU9731198A (en) Histogranin peptide and their analgesic use
ES2192136A1 (es) Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
AP1549A (en) Stabilised hypobromous acid solutions.
CY1108791T1 (el) Φυτοενδυναμωτικο μεσον
RS53304A (en) Ultrapure oral fludara formulation with a fast releasing active substance
AU7308296A (en) Stabilised pharmaceutical compositions containing dobutamine
AU2001248552A1 (en) Water-softener in powdered form with an effervescent system